Patents by Inventor Kapil Mehta
Kapil Mehta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240098069Abstract: Techniques are described that include detecting customer personal information within any appropriate set of data, such as customer communications produced by customer-facing services offered by an organization. Once detected, the customer personal information may be tokenized within the customer communications, making the data appropriate for external systems, such as cloud-hosted applications. The disclosed techniques include a masking service that may be plugged into an on-premises pipeline of any customer-facing service that makes requests to an off-premises, cloud-hosted application. The masking service may apply rule-based detection and/or machine learning-based detection to detect both structured and unstructured customer personal information included in customer communications. The masking service may further tokenize or otherwise obfuscate or replace the detected customer personal information.Type: ApplicationFiled: November 29, 2023Publication date: March 21, 2024Inventors: Chintan Mehta, Michelle Moore, Ramakrishna Swarup Pogalur, Kunal Jha, Kapil Soni, Venkatesan Chinnaraju, Upul D. Hanwella, Ranganathan Kanchi
-
Patent number: 11916674Abstract: Embodiments herein disclose conditioning traffic through multiple data paths of a Software-Defined Wide Area Network (SD-WAN). Some embodiments include monitoring a path through an SD-WAN to reach a destination node, determining a quality score for packets to the destination node on the path, determining a link utilization for the path, sending a data packet sequence to the destination node on the path, generating a forward error correction (FEC) packet for the data packet sequence, and sending the FEC packet to the destination node on the path in response to the quality score being less than a quality threshold and the link utilization being less than a high utilization threshold.Type: GrantFiled: March 31, 2021Date of Patent: February 27, 2024Assignee: Versa Networks, Inc.Inventors: Kapil Bajaj, Apurva Mehta
-
Publication number: 20190105287Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.Type: ApplicationFiled: November 30, 2018Publication date: April 11, 2019Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarwal
-
Patent number: 10182997Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analog encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analog is administered parenterally in a pharmaceutically acceptable carrier.Type: GrantFiled: March 14, 2016Date of Patent: January 22, 2019Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Aggarwal
-
Publication number: 20180318217Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.Type: ApplicationFiled: June 13, 2018Publication date: November 8, 2018Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarwal, Lawrence Helson
-
Patent number: 10004687Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.Type: GrantFiled: May 13, 2014Date of Patent: June 26, 2018Assignees: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, SIGNPATH PHARMA INC.Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal, Lawrence Helson
-
Publication number: 20160193159Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 14, 2016Publication date: July 7, 2016Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Aggarwal
-
Patent number: 9283185Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.Type: GrantFiled: May 27, 2011Date of Patent: March 15, 2016Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarwal
-
Publication number: 20140322303Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.Type: ApplicationFiled: May 13, 2014Publication date: October 30, 2014Applicants: Board of Regents, The University of Texas System, SignPath Pharma Inc.Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal, Lawrence Helson
-
Patent number: 8784881Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.Type: GrantFiled: December 1, 2007Date of Patent: July 22, 2014Assignees: Board of Regents, The University of Texas System, SignPath Pharma Inc.Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal, Lawrence Helson
-
Patent number: 8765797Abstract: Methods and compounds for treating cancer, dmg resistance and/or metastasis are described herein. These methods and compounds can inhibit the expression of aberrant TG2 expression and/or inhibit the binding of GTP to TG2, and thereby prevent the induction of epithelial to mesenchymal transition of cancer cells, and a stem cell-like phenotype.Type: GrantFiled: June 21, 2011Date of Patent: July 1, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Kapil Mehta, Anupam Kumar, Jansina Fok, Shuxing Zhang
-
Publication number: 20130158087Abstract: Methods and compounds for treating cancer, dmg resistance and/or metastasis are described herein. These methods and compounds can inhibit the expression of aberrant TG2 expression and/or inhibit the binding of GTP to TG2, and thereby prevent the induction of epithelial to mesenchymal transition of cancer cells, and a stem cell-like phenotype.Type: ApplicationFiled: June 21, 2011Publication date: June 20, 2013Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Kapil Mehta, Anupam Kumar, Jansina Fok, Shuxing Zhang
-
Patent number: 8299040Abstract: A method for treating cancer comprising inhibiting transglutaminase activity is provided. Suitable cancer types for which the methods of the present disclosure can be used to treat include, but are not limited to, pancreatic, breast, and ovarian cancers and melanoma. The inhibition of transglutaminase activity may be performed by one or more techniques, including, but not limited to, downregulating transglutaminase expression, inhibiting TG2 translation, or blocking TG2 enzymatic activity, such as with a small molecule inhibitor or intracellular antibody (intrabody).Type: GrantFiled: October 5, 2007Date of Patent: October 30, 2012Assignee: Board of Regents, The University of Texas SystemInventors: Kapil Mehta, Amit Verma, Sushovan Guha, Jansina Fok, Gabriel Lopez-Berestein, Anil Sood
-
Publication number: 20110287085Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.Type: ApplicationFiled: May 27, 2011Publication date: November 24, 2011Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat B. Aggarwal
-
Patent number: 7968115Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.Type: GrantFiled: September 7, 2005Date of Patent: June 28, 2011Assignee: Board of Regents, The University of Texas SystemInventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal
-
Publication number: 20080279844Abstract: A method for treating cancer comprising inhibiting transglutaminase activity is provided. Suitable cancer types for which the methods of the present disclosure can be used to treat include, but are not limited to, pancreatic, breast, and ovarian cancers and melanoma. The inhibition of transglutaminase activity may be performed by one or more techniques, including, but not limited to, downregulating transglutaminase expression, inhibiting TG2 translation, or blocking TG2 enzymatic activity, such as with a small molecule inhibitor or intracellular antibody (intrabody).Type: ApplicationFiled: October 5, 2007Publication date: November 13, 2008Inventors: Kapil Mehta, Amit Verma
-
Publication number: 20080138400Abstract: The present invention provides compositions and methods for the treatment of a human patient. The methods and compositions of the present invention include composition for the efficient loading of curcumin, comprising: an amount of a curcuminoid:liposome complex effective to load curcumin into the liposome, wherein the curcuminoids has between 2 to 9 weight percent of the total composition and the curcuminoids are natural or synthetic.Type: ApplicationFiled: December 1, 2007Publication date: June 12, 2008Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: RAZELLE KURZROCK, LAN LI, KAPIL MEHTA, BHARAT BHUSHAN AGGARAWAL, LAWRENCE HELSON
-
Publication number: 20080103213Abstract: The present invention provides a compositions and methods for the treatment of Neurofibromatosis Type 1 and 2, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system to target Merlin and proteins of the Merlin pathway. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.Type: ApplicationFiled: October 5, 2007Publication date: May 1, 2008Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: RAZELLE KURZROCK, LAN LI, KAPIL MEHTA, BHARAT AGGARWAL
-
Patent number: 7223397Abstract: The present invention is directed to the use of agents that induce high levels of cell surface molecules to provide targets for immunotoxins directed against the same cell surface molecules. A specific example is given in which all-trans-retinoic acid (RA) is used to induce high levels of CD38 cell surface antigen expression in several myeloid and lymphoid leukemia cells. CD38 was then used as target for delivering plant toxin (gelonin) to leukemia cells. Treatment of leukemia cells with RA induced high levels of CD38 in those cells that otherwise had low CD38 expression. The RA-induced leukemia cells then became exquisitely sensitive to an immunotoxin constructed from an anti-CD38 monoclonal antibody conjugated to the plant toxin gelonin.Type: GrantFiled: January 7, 1999Date of Patent: May 29, 2007Assignee: Research Development FoundationInventors: Michael Rosenblum, Kapil Mehta
-
Publication number: 20060067998Abstract: The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.Type: ApplicationFiled: September 7, 2005Publication date: March 30, 2006Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Aggarawal